Clinical Report: OLN-324 Shows Extended Drying in DME
Overview
The JADE trial results indicate that OLN-324 demonstrates faster and more durable drying in diabetic macular edema (DME) compared to faricimab. Notably, 93% of patients did not require retreatment from week 12 to week 20.
Background
Diabetic macular edema is a significant cause of vision loss in diabetic patients, making effective treatment essential. Current therapies include various anti-VEGF agents, but there remains a need for improved options that offer faster and sustained responses.
Data Highlights
No numerical data was provided in the source material.
Key Findings
- OLN-324 showed faster and greater drying compared to faricimab through week 12 and maintained this effect to week 24.
- 93% of patients treated with OLN-324 did not require retreatment from week 12 to week 20.
- No cases of intraocular inflammation were reported with OLN-324, contrasting with one case in the faricimab group.
- Upcoming phase 3 trials for OLN-324 are planned for neovascular AMD and DME.
- OLN-324 is a next-generation VEGF/Ang2 bispecific antibody.
Clinical Implications
The results from the JADE trial provide data on OLN-324, which may influence future treatment considerations as more data becomes available.
Conclusion
The JADE trial results for OLN-324 indicate a need for further investigation in upcoming phase 3 trials.
Related Resources & Content
- Ollin Biosciences Reports Positive OLN324 Results, Retinal Physician, 2026 -- OLN-324 Shows Extended Drying in DME
- OCS01 Misses Phase 3 Endpoints in DME, Retinal Physician, 2026 -- OCS-01 Misses Phase 3 Endpoints in DME
- Oculis OCS01 Eye Drop Misses Phase 3 Endpoints in DME, Ophthalmology Management, 2026 -- Oculis OCS01 Eye Drop Misses Phase 3 Endpoints in DME
- Ophthalmology Management — Oculis OCS01 Eye Drops Misses Phase 3 Endpoints in DME
- Standards of Care in Diabetes—2026, American Diabetes Association
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
- Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
